Myasthenia Gravis: An Autoimmune Neuromuscular Junction Disorder

Disease Definition and Classification

• Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction, causing variable muscle weakness that worsens with activity and improves with rest, potentially leading to life-threatening respiratory failure if generalized. 1, 2
• Myasthenia gravis is a B-cell mediated autoimmune disorder affecting the neuromuscular junction, causing muscle weakness and fatigue when antibodies attack components of the neuromuscular junction, disrupting normal transmission of nerve signals to muscles. 3, 1
• Myasthenia gravis has two main types: ocular myasthenia gravis (affecting only the levator, orbicularis oculi, and extraocular muscles) and generalized myasthenia gravis (affecting larger muscle groups and may include ocular features). 1

Disease Mechanism

• Acetylcholine is normally released at the neuromuscular junction during an action potential and crosses the synapse to reach muscle fibers. 1
• In myasthenia gravis, antibodies attack acetylcholine receptors, preventing proper nerve signal transmission. 3
• Acetylcholine receptor antibodies are found in nearly all patients with generalized myasthenia gravis. 2
• Acetylcholine receptor antibodies are found in 40-77% of patients with ocular myasthenia gravis. 1
• Extraocular muscles are particularly susceptible to fatigue due to their twitch fiber composition and fewer acetylcholine receptors. 1

Epidemiology

• Myasthenia gravis affects people of all ages, races, and geographic regions with an incidence of 0.04 to 5 per 100,000 people per year and a prevalence of 0.5 to 12.5 per 100,000 people. 1
• Adult onset myasthenia gravis typically occurs in women during the third to fourth decade of life. 4
• Adult onset myasthenia gravis typically occurs in men later in life. 1
• Thymoma (tumor of the thymus gland) is a risk factor for myasthenia gravis. 1
• Some children may develop transient neonatal myasthenia (passed from mother), congenital myasthenia (not immune-mediated), or juvenile autoimmune myasthenia. 1

Clinical Presentation

• Ocular symptoms, often the first to appear in myasthenia gravis, include drooping eyelids (ptosis). 1
• Double vision (diplopia) is a common ocular symptom of myasthenia gravis. 2
• Variable strabismus (misalignment of eyes) is a characteristic ocular symptom of myasthenia gravis. 1, 2
• Generalized myasthenia gravis symptoms include difficulty chewing and swallowing, and slurred speech. 4
• Difficulty holding up the head is a symptom of generalized myasthenia gravis. 2
• Respiratory muscle weakness is a serious manifestation of generalized myasthenia gravis. 1, 4

Key Clinical Characteristics

• Fluctuating weakness is characteristic of myasthenia gravis, with symptoms worsening with continued activity and improving with rest. 1
• Fatiguability is a hallmark of myasthenia gravis, with symptoms worsening as the day progresses or with repetitive use of affected muscles. 1
• Variable presentation is typical in myasthenia gravis, with the pattern of weakness changing during examination. 1
• Myasthenia gravis is considered a "great masquerader" as it can mimic many types of eye movement disorders. 3
• Temporary improvement of symptoms with rest or application of ice (ice pack test) is characteristic of myasthenia gravis. 1

Natural History and Complications

• 50% of myasthenia gravis patients initially present with ocular symptoms only. 1
• 50-80% of those with initial ocular symptoms develop generalized myasthenia within a few years. 1
• If generalized, myasthenia gravis can involve bulbar, limb, and respiratory muscles. 1
• Respiratory failure requiring ventilatory support is a life-threatening complication of myasthenia gravis. 1

Diagnosis

• Diagnosis of myasthenia gravis is based on clinical presentation of fluctuating muscle weakness. 1
• Characteristic findings in myasthenia gravis include variable strabismus and ptosis that worsen with fatigue. 1
• Slow ocular saccades (rapid eye movements) are characteristic findings in myasthenia gravis. 1

Treatment Approach

• Treatment goals for myasthenia gravis include preventing morbidity and mortality from generalized myasthenia gravis, reducing double vision, improving eye alignment, and restoring normal appearance and function. 1
• Thymectomy (surgical removal of the thymus gland) is a treatment approach for myasthenia gravis, especially if thymoma is present. 1

Clinical Management

• Early recognition of myasthenia gravis is crucial as prompt diagnosis allows for appropriate treatment and prevention of complications. 1
• Neurologist referral is essential for proper management of myasthenia gravis. 1
• Monitoring for respiratory compromise is critical to prevent life-threatening complications in myasthenia gravis. 1

Clinical Manifestations and Management of Myasthenia Gravis

Bulbar Manifestations

• Dysarthria (slurred speech) and dysphagia (difficulty swallowing) are common bulbar manifestations of myasthenia gravis, according to the Journal of Clinical Oncology guidelines, affecting patients with this condition 5
• Facial muscle weakness causing reduced facial expressions is a characteristic feature of myasthenia gravis, as reported in the Journal of Clinical Oncology, and can impact patients' quality of life 5

Limb and Axial Muscle Involvement

• Proximal muscles are affected more than distal muscles in myasthenia gravis, as noted in the Journal of Clinical Oncology, leading to weakness and mobility issues 5
• Neck weakness leading to difficulty holding up the head is a significant symptom of myasthenia gravis, as described in the Journal of Clinical Oncology, and can affect patients' daily activities 5

Respiratory Manifestations

• Respiratory muscle weakness represents the most life-threatening manifestation of myasthenia gravis, according to the Journal of Clinical Oncology, and can rapidly progress to respiratory insufficiency or failure (myasthenic crisis) 5
• Close monitoring with pulmonary function tests, including negative inspiratory force (NIF) and vital capacity (VC), is crucial in managing respiratory manifestations of myasthenia gravis, as recommended by the Journal of Clinical Oncology 5

Clinical Classification by Severity

• The Myasthenia Gravis Foundation of America (MGFA) classification system guides management, with Class I representing ocular symptoms only, Class II representing mild generalized weakness, Class III representing moderate generalized weakness, Class IV representing severe generalized weakness, and Class V representing myasthenic crisis requiring intubation and ventilatory support, as outlined in the Journal of Clinical Oncology 5

Critical Pitfalls to Avoid

• All grades of myasthenia gravis warrant thorough work-up and intervention given the potential for progressive disease leading to respiratory compromise, as emphasized by the Journal of Clinical Oncology, and failure to recognize early respiratory involvement can be fatal 5
• Certain medications, such as beta-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics, can precipitate or worsen myasthenic weakness and should be avoided, as warned by the Journal of Clinical Oncology 5

Concurrent Conditions to Consider

• Myasthenia gravis may occur with myositis and/or myocarditis, requiring evaluation with CPK, aldolase, troponin T, ECG, and echocardiography if respiratory insufficiency or elevated CPK is present, as recommended by the Journal of Clinical Oncology 5
• Respiratory symptoms may require evaluation to rule out pneumonitis or myocarditis, as suggested by the Journal of Clinical Oncology, to ensure proper diagnosis and management 5

Myasthenia Gravis Clinical Characteristics

Ocular and Bulbar Manifestations

• Ptosis (drooping eyelids) is often the first symptom, appearing unilateral or bilateral, and characteristically worsens with prolonged upgaze or fatigue, according to the American Academy of Ophthalmology 6
• Diplopia (double vision) results from extraocular muscle weakness and is highly variable, as reported by the American Academy of Ophthalmology 6
• Dysarthria (slurred speech) is common as facial and pharyngeal muscles fatigue, as noted by the American Academy of Ophthalmology 6
• Dysphagia (difficulty swallowing) affects many patients and worsens with prolonged chewing, according to the American Academy of Ophthalmology 6

Limb and Respiratory Involvement

• Proximal muscle weakness affecting shoulders and hips more than distal muscles is a characteristic feature, as reported by the American Society of Clinical Oncology 7
• Respiratory muscle weakness represents the most serious manifestation and can rapidly progress to respiratory failure (myasthenic crisis), according to the American Society of Clinical Oncology 7
• Respiratory fatigue with shortness of breath, particularly with exertion, is a common symptom, as noted by the American Academy of Ophthalmology 6

Diagnostic Considerations

• Pupils are typically NOT affected—pupillary involvement should alert you to consider alternative diagnoses such as third nerve palsy, as reported by the American Academy of Ophthalmology 6
• Failure to recognize early respiratory involvement can be fatal—all grades warrant thorough evaluation given potential for progression to respiratory compromise, according to the American Society of Clinical Oncology 7

Myasthenia Gravis Diagnosis and Management

Clinical Features and Diagnostic Confirmation

• The American Academy of Neurology recommends that patients with myasthenia gravis be evaluated for fatigable weakness, fluctuating ocular symptoms, and bulbar involvement, with diagnostic confirmation required through acetylcholine receptor antibody testing, repetitive nerve stimulation, or single-fiber EMG 8, 9
• Patients with generalized myasthenia gravis, such as those with MGFA Class II, require immediate work-up and intervention due to the potential for rapid progression to respiratory compromise, with a focus on assessing for respiratory muscle involvement through pulmonary function testing 8, 9
• The presence of muscle-specific kinase (MuSK) antibodies or lipoprotein-related protein 4 (LRP4) antibodies should be tested for in seronegative patients, with a positive result confirming neuromuscular junction pathology 8, 9

Management Considerations

• The American College of Chest Physicians recommends that patients with myasthenia gravis undergo chest CT to screen for thymoma, which is present in 10-15% of patients and requires different management 8, 9
• Certain medications, such as beta-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics, can precipitate myasthenic crisis and must be avoided in patients with myasthenia gravis 8, 9
• Patients with myasthenia gravis should be monitored for concurrent myositis or myocarditis through CPK, troponin, ECG, and echocardiography if indicated, as these can co-occur with myasthenia gravis 8, 9

Autoantibodies in Myasthenia Gravis

Mechanism of Antibody Action

• The autoantibodies in myasthenia gravis are inhibitory, preventing acetylcholine from activating receptors at the neuromuscular junction, as stated by the American Academy of Neurology, they do not stimulate the junction 10, 11
• These antibodies cause the neuromuscular junction to function as though fewer receptors are present, manifesting as increased sensitivity to neuromuscular blocking agents, according to the American College of Physicians 10, 11, 12

Clinical Implications of Inhibitory Mechanism

• Response to acetylcholinesterase inhibitors works by increasing acetylcholine concentration in the synaptic cleft to overcome the receptor blockade, as recommended by the American Academy of Neurology 10, 11

Critical Distinction from Stimulatory Conditions

• MG antibodies are never stimulatory, they exclusively block, inhibit, or destroy neuromuscular junction components, as stated by the European Neurological Society 13

Clinical Guidance for History‑Taking in Myasthenia Gravis

Bulbar and Facial Manifestations

• Facial weakness (reduced facial expression or difficulty with facial movements) should be specifically queried as a common bulbar symptom of myasthenia gravis. [14][15]

Immune Checkpoint Inhibitor–Related Myasthenia

• Recent treatment with immune checkpoint inhibitors (e.g., anti‑PD‑1/PD‑L1 or CTLA‑4 antibodies) can precipitate myasthenia gravis as an immune‑related adverse event. [14][15]16

Medication‑Related Diagnostic Confounders

• Current statin therapy may cause myopathy that mimics or obscures myasthenic weakness and should be identified during history‑taking. [14][15]

Associated Autoimmune Conditions

• A history of other autoimmune diseases—including thyroid disease, systemic lupus erythematosus, and rheumatoid arthritis—is frequently associated with myasthenia gravis. 17

Red‑Flag Indicators of Myasthenic Crisis

• Severe dysphagia with a high risk of aspiration constitutes a critical red‑flag sign of impending myasthenic crisis. 18
• The coexistence of myocarditis or myositis—particularly in patients receiving immune checkpoint inhibitors—significantly raises mortality risk and warrants urgent evaluation. [14][15]18

Distinguishing Features and Differential Diagnosis

Myasthenia Gravis Evidence‑Based Recommendations

Serologic Testing in Suspected MG

• In patients who test negative for acetylcholine‑receptor antibodies, approximately one‑third will have muscle‑specific kinase (anti‑MuSK) antibodies, supporting further testing. 20
• Lipoprotein‑related protein 4 (LRP4) antibodies are recommended as an additional assay in seronegative cases to improve diagnostic yield. 20

Pharmacologic Management (Neurology‑Directed)

• Pyridostigmine bromide, given orally 2–4 times daily, achieves clinical improvement in only about 50 % of patients whose disease is limited to ocular symptoms. 20
• Systemic corticosteroids produce a favorable response in 66–85 % of MG patients, making them a cornerstone of early immunotherapy. 20
• Immunosuppressive agents such as azathioprine are frequently required as steroid‑sparing or adjunctive therapy in patients with inadequate response to first‑line drugs. 20

Surgical Considerations

• Thymectomy is indicated when a thymoma is identified on imaging and can lead to substantial reduction of MG symptoms. 20

Primary‑Care Referral Guidance

• Initiation of disease‑specific therapy should be deferred in primary‑care settings; definitive management must be overseen by a neurologist experienced in MG. 20

Evidence‑Based Recommendations for Myasthenia Gravis Diagnosis

Respiratory Assessment

• In patients with suspected myasthenia gravis who exhibit bulbar or respiratory symptoms, urgent pulmonary function testing—including negative inspiratory force (NIF) and vital capacity measurements—should be performed to identify impending respiratory failure. 21

• For any patient with generalized myasthenic symptoms, routine assessment of respiratory function (NIF and vital capacity) is indicated to detect early compromise. 21

Neuroimaging

• Brain magnetic resonance imaging (MRI) should be considered when atypical features are present or when central lesions (e.g., brainstem stroke) need to be excluded as mimics of myasthenia gravis. 21

Differential Diagnosis – Guillain‑Barré Syndrome

• Guillain‑Barré syndrome (GBS) can be distinguished from myasthenia gravis by its characteristic presentation of ascending weakness, sensory involvement, and reduced or absent deep‑tendon reflexes. 21

• Cerebrospinal fluid analysis in GBS typically shows an elevated protein level with a normal white‑cell count, a pattern not seen in myasthenia gravis. 21

• Nerve conduction studies in GBS reveal an acute polyneuropathy pattern, aiding differentiation from myasthenic neuromuscular transmission defects. 21

Medication‑Related Triggers

• Clinicians should review medication histories because agents such as beta‑blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolides can precipitate or exacerbate myasthenic weakness. 21

Bedside Diagnostic Tests and Thymic Associations in Myasthenia Gravis

Bedside Diagnostic Clues

• Ice‑pack test – Applying an ice pack over closed eyes for 2 minutes (ptosis) or 5 minutes (strabismus) produces a reduction of ptosis of roughly 2 mm or improves ocular alignment, providing a highly specific bedside indicator of myasthenia gravis because cooling diminishes acetylcholinesterase activity. 22

• Rest test – Symptoms improve after several minutes of rest with the eyes closed, which also supports a diagnosis of myasthenia gravis. 22

Thymic Associations

• Thymoma co‑occurrence – About one‑third of patients with thymoma have concurrent myasthenia gravis, indicating that routine MG screening is warranted in individuals diagnosed with thymoma. 23

• Thymoma prevalence in seropositive MG – Thymoma is present in 10–20 % of patients who test positive for acetylcholine‑receptor antibodies, reflecting a notable overlap between thymic neoplasia and antibody‑positive myasthenia gravis. 23